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utations in 
 
GDAP1
 
 lead to severe forms of the
peripheral motor and sensory neuropathy,
Charcot-Marie-Tooth disease (CMT), which is
characterized by heterogeneous phenotypes, including
pronounced axonal damage and demyelination. We
show that neurons and Schwann cells express gan-
glioside-induced differentiation associated protein 1
(GDAP1), which suggest that both cell types may con-
tribute to the mixed features of the disease. GDAP1 is
located in the mitochondrial outer membrane and regu-
lates the mitochondrial network. Overexpression of
GDAP1 induces fragmentation of mitochondria without
inducing apoptosis, affecting overall mitochondrial ac-
M
 
tivity, or interfering with mitochondrial fusion. The mi-
tochondrial fusion proteins, mitofusin 1 and 2 and
Drp1(K38A), can counterbalance the GDAP1-dependent
ﬁssion. GDAP1-speciﬁc knockdown by RNA interfer-
ence results in a tubular mitochondrial morphology.
GDAP1 truncations that are found in patients who have
CMT are not targeted to mitochondria and have lost mi-
tochondrial fragmentation activity. The latter activity
also is reduced strongly for disease-associated GDAP1
point mutations. Our data indicate that an exquisitely
tight control of mitochondrial dynamics, regulated by
GDAP1, is crucial for the proper function of myelinated
peripheral nerves.
 
Introduction
 
Charcot-Marie-Tooth disease (CMT) is the most frequent in-
herited peripheral neuropathy in humans; it affects 1 in 2,500
people (Berger et al., 2002). CMT is grouped into demyelinat-
ing and axonal forms according to electrophysiologic and
pathologic findings. The defects in demyelinating types are be-
lieved to originate in myelinating Schwann cells, whereas neu-
rons are first affected in axonal forms. However, recent studies
on the molecular and cellular basis of CMT suggest that this
distinction might not be absolute (Berger et al., 2002; Suter and
Scherer, 2003). Demyelinating forms are associated with re-
duced nerve conduction velocity, segmental de- and remyelina-
tion, and “onion bulb” formations (CMT1, CMT3, and CMT4).
The axonal forms (CMT2) show axonal degeneration without
overt demyelinating lesions (Berger et al., 2002; Suter and
Scherer, 2003). Among the recessive forms, the subtype
CMT4A is the most frequent (Nelis et al., 2002), and disease-
associated mutations in 
 
GDAP1
 
 (ganglioside-induced differen-
tiation associated protein 1) have been identified. Initially,
Baxter and colleagues (2002) reported patients with an early
onset of the disease and severe symmetric weakness and atro-
phy of the feet and hands. Motor and sensory nerve conduction
velocities were reduced which was consistent with a demy-
elinating form of CMT (Baxter et al., 2002). Cuesta et al. (2002)
described a classic axonal phenotype, without apparent demy-
elination, with hoarse voice and vocal cord paresis as additional
symptoms that was associated with other mutations in 
 
GDAP1
 
.
Later, even patients with an identical mutation (homozygous
GDAP1 S194X) were depicted with demyelinating or axonal
phenotypes (Baxter et al., 2002; Nelis et al., 2002). Today, ap-
proximately 20 CMT-associated 
 
GDAP1
 
 alterations, including
point mutations and changes leading to truncated proteins
(see Online Mendelian Inheritance in Man [OMIM] number
*606598), have been described, causing axonal, demyelinating,
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or intermediate forms (Di Maria et al., 2004). No obvious
correlation between the position and nature of the mutations
and the electrophysiologic or neuropathologic phenotype
could be discerned. Thus, the issue of axonal versus demy-
elinating phenotypes and the cellular origin and basis of the
disease remain open.
The available information about the biology of GDAP1 is
scarce. GDAP1 was identified as a transcript that was up-regu-
lated after ganglioside-induced cholinergic differentiation of
the mouse neuroblastoma cell line Neuro2a (Liu et al., 1999).
Furthermore, an increase of GDAP1 mRNA expression also
was found in neural-differentiated P19 cells and during devel-
opment of the mouse brain (Liu et al., 1999).
Some hints about the molecular function of GDAP1 have
been provided by bioinformatic analyses (Marco et al., 2004)
confirming and extending previous reports (Baxter et al., 2002;
Cuesta et al., 2002; Nelis et al., 2002). These studies demon-
strated that GDAP1 and related proteins in invertebrates
and vertebrates contain the characteristic domains of GSTs
(GST-N, GST-C). Based on its particular domain features,
GDAP1 was proposed as the founder of a new GST family.
Members of this family are characterized by an enlarged inter-
domain between the GST-N and GST-C domains, and contain
COOH-terminal hydrophobic stretches with potential trans-
membrane features (Marco et al., 2004).
Here we show that Schwann cells and neurons of my-
elinated peripheral nerves express GDAP1. Thus, both cell
types might be affected directly by the consequences of
the disease-causing mutations in 
 
GDAP1
 
. Within the cell,
GDAP1 functions as a tail-anchored protein of the mitochon-
drial outer membrane and promotes fragmentation of mito-
chondria. On this basis, we define GDAP1 as a novel regulator
of the mitochondrial network. This ability is lost or reduced in
CMT-associated mutated forms of GDAP1 and is very likely
to contribute to the axonal and/or demyelinating defects that
are seen in patients. The precise regulation of fusion and fission
of mitochondria seems to be crucial for the integrity of the
peripheral nervous system (PNS).
 
Results
 
GDAP1 is expressed by myelinating 
Schwann cells and neurons of the PNS
 
To examine the function of GDAP1 in peripheral nerves and
to determine its role in neuropathies, we developed rabbit an-
tisera against two GDAP1-specific peptides (Fig. S1; avail-
able at http://www.jcb.org/cgi/content/full/jcb.200507087/
DC1). Western blot analysis of extracts that were derived
from various neural tissues revealed that GDAP1 is expressed
most prominently in different regions of the central nervous
system, including the cortex, cerebellum, thalamus, olfactory
bulb, and spinal cord (Fig. 1 A). Consistent with the conse-
quences of GDAP1 mutations leading to motor and sensory
neuropathies, we also found GDAP1 expression in sciatic
nerves and in dorsal root ganglia (DRG) (Fig. 1 A). The re-
sults were identical with antisera against each of the two
GDAP1 peptides (unpublished data). Furthermore, the levels
of GDAP1 protein correlated well with parallel measurements
of GDAP1 transcripts that were determined by quantitative
RT-PCR (unpublished data) and with previously published
data (Cuesta et al., 2002).
In humans, the most prominent result of mutations in
 
GDAP1
 
 is a pronounced motor and sensory neuropathy with
a remarkable variability in phenotypic expression that ranges
from primarily demyelinating to strong axonal involvement,
and mixed forms with both alterations. Unraveling this com-
plex situation, in efforts to clarify the underlying disease
mechanisms, requires the determination of whether GDAP1
is expressed exclusively by only one of the two cell types in-
volved—Schwann cells or neurons—or both. Such an analy-
sis recently elucidated that mutations in the N-myc down-
stream-regulated gene 1 (
 
NDRG1
 
) primarily target myelinating
Schwann cells in the hereditary motor and sensory neurop-
athy-Lom (Berger et al., 2004). Thus, we have analyzed the
expression of GDAP1 in peripheral nerves in detail. GDAP1
was found in cross sections of rat sciatic nerves and colocal-
ized with the Schwann cell marker S100 (Fig. 1 B, a–c) and
Figure 1. GDAP1 protein is expressed in Schwann cells and neurons.
(A) 15  g of protein lysate from the indicated neuronal tissues was ana-
lyzed by Western blot. In all tissues tested, GDAP1 was detected at the
predicted size of 41.5 kD (arrowhead). The expression was highest in
central nervous system tissues. The additional weak bands at  48 kD and
 75 kD were not detected with another GDAP1 antiserum, and thus,
were considered to be unspecific. (B) GDAP1 expression on cryosections
of rat sciatic nerve. The signal colocalizes on single-plane confocal pic-
tures (0.5- m sections) with the Schwann cell marker S100 (1B, a–c) and
the neuronal marker neurofilament (1B, d–f). Bars, 10  m. 
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the neuronal marker neurofilament (Fig. 1 B, d–f; neurofila-
ment-positive axons stained for GDAP1 with punctuated pat-
terns). Consistent with these observations, the cell bodies of
motoneurons in the spinal cord (not depicted) and sensory
neurons in DRG (Fig. S2; available at http://www.jcb.org/
cgi/content/full/jcb.200507087/DC1) were labeled with anti-
GDAP1 antibodies. The specificity was confirmed by success-
ful blocking of the staining by preincubation of the serum with
the antigenic peptide (Fig. S2), and concordant results for
GDAP1 mRNA expression were obtained by in situ hybrid-
ization on spinal cord and DRG sections (not depicted).
Teased sciatic nerve fiber preparations revealed that GDAP1
is present in the cytoplasm of myelinating Schwann cells,
with particularly strong staining in the perinuclear region and
Schmidt-Lanterman incisures (unpublished data). We con-
clude that PNS neurons and Schwann cells, both commonly
involved in the etiology of motor and sensory neuropathies,
express GDAP1 with potential functional implications.
 
GDAP1 is a mitochondrial protein
 
We next determined the precise subcellular localization of
GDAP1. In COS-7 cells that were transfected with an untagged
GDAP1 full-length expression construct, we found GDAP1
in distinct structures with tubular and vesicular appearances
throughout the cytoplasm at the onset of expression (Fig. 2 A).
These GDAP1-positive formations were identified as mito-
chondria by congruent costaining with the mitochondrial mark-
ers MitoTracker (Fig. 2 A, a–d), cytochrome 
 
c
 
 (Fig. 4 B), and
porin (not depicted). No appreciable overlap was found with
other membranous compartments, including the Golgi complex
(marker giantin; Fig. 2 A, e–h) or the ER (marker protein disul-
fide isomerase [PDI]; Fig. 2 A, i–l).
To exclude potential localization artifacts that are due to
overexpression, we also examined the intracellular confinement
of endogenous GDAP1. In agreement with previous results, we
found GDAP1 staining of mitochondria in Neuro2a (Liu et al.,
1999), N1E-115 cells, C2C12 cells (not depicted), and primary
Schwann cells in culture (Fig. S2). Finally, GDAP1 and porin
colocalized in sections of rat DRG (Fig. S2).
To support further the localization of GDAP1 to mito-
chondria, we used a cell fractionation approach. Mitochondria
were enriched by differential centrifugation (Graham, 2004),
and the various steps were analyzed by Western blotting. Cell
fractionations were performed with transfected Cos-7 cells (not
depicted) and with endogenously GDAP1-expressing N1E-115
cells (Fig. 2 B). As expected, GDAP1 levels were enhanced
specifically by this procedure in parallel with porin, an abun-
dant transmembrane protein of the outer mitochondrial mem-
brane, and in contrast to proteins of the ER, like PDI. Thus,
GDAP1 is located in mitochondria.
Figure 2. GDAP1 is a mitochondrial protein. (A) Trans-
fected COS-7 cells, 12 h after transfection with GDAP1
expression constructs. GDAP1 colocalizes with the mito-
chondrial marker MitoTracker Red (a–d), but not with the
Golgi complex marker giantin (e–h) or the ER marker PDI
(i–l) on single-plane confocal pictures (0.4- m sections).
Bars in c, g, and k, 10  m; bars in d, h, and l, 2  m.
Boxes in c, g, and k indicate the magnified areas in d,
h, and l. (B) Mitochondria from endogenously GDAP1-
expressing N1E-115 cells were enriched in a differential
centrifugation approach. 20  g of protein yielded by the
centrifugation steps were loaded per lane. The mitochon-
drial protein porin and GDAP1, but not the ER protein
PDI, showed increased levels in the pellets. 
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GDAP1 is an integral membrane protein 
of the outer mitochondrial membrane
 
To elucidate the localization of GDAP1 within the mitochon-
dria, we purified mitochondria from COS-7 cells, 24 h after
transfection with a GDAP1 expression construct. Mitochondria
were resuspended and digested with an excess of proteinase K
in the presence or absence of detergent (Olichon et al., 2002),
and analyzed by Western blot. The GDAP1 signal was lost
upon proteinase incubation, whereas cytochrome 
 
c
 
, located in
the intermembrane space, was protected and disappeared only
if increasing amounts of digitonin or SDS were added (Fig. 3 A).
Because the antisera used in this analysis recognize the NH
 
2
 
-
terminal proximal segment of GDAP1 (Fig. S1), these data in-
dicate that the NH
 
2
 
 terminus of GDAP1, and thereby, the GST
domains, are exposed to the cellular cytoplasm. In support of
this interpretation, we found GDAP1 in the outer mitochondrial
membrane by ultrastructural analysis using immunogold label-
ing (unpublished data).
We next asked whether GDAP1 is associated peripher-
ally with mitochondrial membranes or whether it is an integral
membrane protein as proposed (Marco et al., 2004). Isolated
mitochondria were resuspended in various buffers and, after
centrifugation, supernatants and membranous pellets were ana-
lyzed by Western blotting (Sogo and Yaffe, 1994; Olichon et
al., 2002; Stojanovski et al., 2004) (Fig. 3 B). GDAP1 re-
mained associated with the mitochondrial pellet after treatment
with 1 M sodium chloride or 0.1 M carbonate buffer (pH 11).
Detergent treatment released GDAP1 to the supernatant, com-
parable to the integral membrane protein porin. Together, these
experiments demonstrate that GDAP1 is an integral membrane
protein of the outer mitochondrial membrane.
 
GDAP1 regulates the architecture of 
mitochondria
 
In various experiments, we observed time-dependent changes
in the mitochondrial morphology upon GDAP1 transfection.
With prolonged expression of GDAP1, the mitochondria in
COS-7 cells became more fragmented, and tubular forms were
less prominent (Fig. 4 A, c and d). This effect was not seen in
mock-transfected cells (Fig. 4 A, a). We reasoned that overex-
pression of any protein of the outer mitochondrial membrane
could cause this effect. However, mitochondrial morphology
was not appreciably altered upon transient expression of the
GFP-tagged human transporter of the outer membrane subunit
7 (EGFP-hTOM7), in agreement with previous results (Stoja-
novski et al., 2004) (Fig. 4 A, b). This indicates a specific effect
of GDAP1 in our experimental settings. Thus, we quantified
the morphologic alterations caused by GDAP1 overexpression.
To this end, we defined five distinct mitochondrial architec-
tures within cells (for examples, see Fig. 4 A, e, bottom panel):
perinuclear aggregated (“aggregated”), predominantly tubular
(“tubular”), tubular and vesicular (“mixed”), predominantly ve-
sicular but with some tubular structures (“vesicular”), and com-
pletely vesicular or fragmented mitochondria (“fragmented”).
This analysis revealed that 15 h after transfection with GDAP1,
fragmented mitochondria increase significantly at the expense
of tubular and mixed mitochondrial formations compared with
control cells (Fig. 4 A, e). As suspected from our previous im-
pressions, this shift toward mitochondrial fragmentation was
even more pronounced 20 h after transfection.
 
GDAP1-induced fragmentation is not 
associated with defective overall 
mitochondrial physiology
 
Fragmentation of mitochondria can occur in response to apop-
totic stimuli (Lee et al., 2004). Thus, we tested whether GDAP1
overexpression induces apoptosis. Initial qualitative observa-
tions of transiently transfected HeLa, Neuro2a, or COS-7 cells
did not suggest massive induction of apoptosis. To analyze this
issue more precisely, we transfected HeLa cells with GDAP1 or
EGFP-hFis1, a protein that is known to induce mitochondrial
fission and apoptosis (James et al., 2003); fixed the cells after
36 h; and stained for cytochrome 
 
c
 
 and GDAP1. As anticipated,
EGFP-hFis1 promoted the release of cytochrome 
 
c
 
 (note the dif-
fuse cytochrome c staining exclusively in the transfected cell,
Fig. 4 B, d), whereas in cells expressing GDAP1, cytochrome 
 
c
 
was restricted to mitochondria (Fig. 4 B, a and b).
Loss of the mitochondrial transmembrane potential
(
 
  
 
m) also triggers the fragmentation of mitochondria (Legros
et al., 2002). Thus, we asked whether the fragmentation that is
induced by overexpression of GDAP1 might be secondary to an
effect on 
 
  
 
m. The uptake of the dye, MitoTrackerH
 
2
 
XRos,
into mitochondria is dependent on mitochondrial activity (Chen
and Cushion, 1994), which provides a mean to test this possibil-
ity (Fig. 4 C, a and b). Transient transfection with low amounts
of an EGFP-hFis1 expression construct served as positive con-
Figure 3. GDAP1 is a transmembrane protein of the outer mitochondrial
membrane. (A) A crude mitochondrial extract of transfected COS-7 cells
was digested with proteinase K in the presence of increasing concentrations
of digitonin. The digest was stopped after 30 min on ice with an excess of
PMSF, and was analyzed by Western blot. The signal for GDAP1 was lost
in the absence of digitonin. Cytochrome c was protected against the digest
until the mitochondrial outer membrane was permeabilized with high con-
centrations of digitonin, or with SDS (bottom lane). (B) The mitochondrial
pellet of transfected COS-7 cells was resuspended in buffer (control), in 1 M
NaCl, in 0.1 M carbonate (pH 11), or in buffer with 0.1% Triton X-100,
and centrifuged to separate the soluble protein supernatants from membra-
nous pellets. GDAP1 and the known transmembrane protein porin are
found in the supernatant only in the presence of detergent. 
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trol (Yoon, 2004). Dye uptake was unchanged in GDAP1-
expressing cells compared with nontransfected HeLa cells,
whereas it was reduced to 70% in EGFP-hFis1–positive HeLa
cells. In addition, we generated stably transfected Neuro2a cells
that inducibly overexpress GDAP1. Using 5,5
 
 
 
,6,6
 
 
 
-tetrachloro-
1,1
 
 
 
,3,3
 
 
 
-tetraethylbenzimidazolcarbocyanine iodide in flow cy-
tometry (Cossarizza et al., 1993), we confirmed that overexpres-
sion of GDAP1 does not induce apoptosis or influence 
 
  
 
m in
these cells (unpublished data).
 
GDAP1-induced mitochondrial 
fragmentation is blocked by dynamin-
related protein 1 (K38A) coexpression 
and counterbalanced by mitofusin 1 and 2
 
The shape of mitochondria depends on the balance of fusion and
fission. Thus, we tested whether the induction of fragmentation
by GDAP1 can be counterbalanced by proteins that are known
to induce fusion or block fission. The dynamin-related protein 1
(Drp1) plays a central role in the fission of mitochondria; the
dominant-negative Drp1(K38A) form blocks mitochondrial
fission (Smirnova et al., 1998). We coexpressed GDAP1 with
Drp1 or Drp1(K38A) in COS-7 cells, and analyzed the mito-
chondrial morphology of cells that express both proteins 17 h
after transfection. Western blotting confirmed comparable ex-
pression levels of the transfected constructs (unpublished data).
Coexpression of GDAP1 and Drp1 did not influence GDAP1-
induced mitochondrial fragmentation considerably (Fig. 5 A, a–f).
This outcome was expected, because overexpression of Drp1
per se does not change the mitochondrial architecture; there is
an abundant pool of endogenous Drp1 in the cell (Yoon, 2004).
In contrast, if coexpressed with GDAP1, Drp1(K38A) partially
inhibited the fragmentation of mitochondria (Fig. 5 A, g–i). An
increased number of GDAP1-Drp1(K38A) doubly expressing
cells still had fragmented mitochondria compared with EGFP-
hTOM7 control-transfected cells; however, this number was re-
duced significantly compared with GDAP1-only expressing
cells (Fig. 5 A, j). Also, more cells than controls showed
extended tubular mitochondrial morphology, the most promi-
nent phenotype observed when Drp1(K38A) is expressed
alone (85%; unpublished data). In summary, coexpression of
Figure 4. GDAP1 promotes mitochondrial
fission. (A, a) Untransfected COS-7 cells dis-
play vesicular and tubular mitochondria, la-
beled with MitoTracker Red. (b) Transient
transfection with the mitochondrial EGFP-fusion
protein hTOM7 does not change this appear-
ance. (c) The mitochondrial architecture is al-
tered to a partially fragmented appearance
15 h after transfection with GDAP1. (d) After
20 h, most mitochondria are fragmented. (e)
The morphologic results were quantified by
classifying the appearance of mitochondria in
GDAP1-expressing cells. Representative im-
ages for aggregated, tubular, mixed, vesicu-
lar, and fragmented mitochondrial appear-
ance are shown. Bars: (a–d) 10  m, (e) 5  m.
 500 transfected cells per condition from
three independent experiments were counted.
All changes are highly significant (probabil-
ity   chi square   0.001, comparing all con-
ditions versus control transfected cells in a con-
tingency analysis using JMP 5 [JMP Discovery]).
(B) HeLa cells were transfected transiently with
GDAP1 (a, b), or 0.5  g plasmid DNA cod-
ing for the fission factor EGFP-hFis1 (c, d) and
fixed 36 h after transfection. The expression
of EGFP-Fis1 leads to a release of cytochrome
c into the cytoplasm (c, d). Exclusive mito-
chondrial localization of cytochrome c was
observed in cells expressing GDAP1 (a, b).
(C) The mitochondrial uptake of the dye
MitoTrackerH2XRos into HeLa cells is depen-
dent on the activity of the mitochondria (a)
and can be blocked with the protonophore
cccp (b; 10  M, 45 min) (b). HeLa cells were
transfected with expression constructs for
EGFP-hFis1 (0.25  g; c, d) and GDAP1 (0.5
 g; e, f) and labeled with MitoTrackerH2Xros,
24 h after transfection. HeLa cells expressing
EGFP-hFis1 display a weaker mitochondrial
staining with MitoTrackerH2Xros (dashed
green area) compared with untransfected
cells (dashed blue box) (c, d). No difference
between cells expressing GDAP1 and un-
transfected cells was found (compare dashed
green and blue area) (e, f). The observation shown on the representative confocal images (a–f) was quantified using ImageJ (NIH) on 15 independent
confocal pictures from three independent experiments (g; n, number of cells). Bars, (B and C) 10  m. 
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Drp1(K38A) can block GDAP1-induced fragmentation par-
tially, but without restoring the normal pattern completely.
Mitofusin (Mfn) 1 and 2 are essential for mitochondrial
fusion and maintenance of mitochondrial morphology (Chen et
al., 2003; Rojo et al., 2002; Santel and Fuller, 2001; Santel et al.,
2003;). We found that coexpression of GDAP1 and Mfn1 or
Mfn2 led to a balanced mitochondrial architecture, similar to the
morphology observed in untransfected or EGFP-hTOM7 con-
trol-transfected cells (Fig. 5 B, a and c; compare with Fig. 4 A,
a and b). Quantification confirmed that the coexpression of
GDAP1 with Mfn1 or Mfn2 rescues GDAP1-induced mito-
chondrial fragmentation (Fig. 5 B, e). This effect is specific and
depends on the activity of Mfn’s because altered forms of Mfn1
and Mfn2 that carry mutations in their GTPase G1 motives
(Mfn1[K88T] and Mfn2[K109A]) (Chen et al., 2003), were un-
able to prevent GDAP1-induced fragmentation (Fig. 5 B, b, d,
e). We conclude that GDAP1 and Mfn’s can counterbalance
their opposite effects on structural mitochondria dynamics.
 
GDAP1 does not reduce mitochondrial 
fusion
 
Our previous experiments have shown that the overexpression
of GDAP1 promotes mitochondrial fragmentation. This mito-
chondrial morphology might result from increased mitochon-
drial fission, reduced mitochondrial fusion, or a combination of
both effects. Using polyethylene glycol (PEG)-based cell fusion
technique, we examined the effect of GDAP1 on mitochondrial
fusion (Mattenberger et al., 2003). HeLa cells that were trans-
fected transiently with mitochondrial targeted DsRed (mtDsRed)
were coplated with HeLa cells that were transfected transiently
with mitochondrial targeted GFP (mtGFP; see Fig. 7, a–c) or
GDAP1 (see Fig. 7, d–f). The cells were fused with PEG and
cultivated in the presence of cycloheximide. As reported previ-
ously, we found mitochondrial fusion in hybrids of cells trans-
fected with mtDsRed fused to cells transfected with mtGFP 3–4 h
after cell fusion. This process was almost complete 6 h after cell
fusion (Fig. 6, a–c, g; Mattenberger et al., 2003). An identical
Figure 5. GDAP1-induced fragmentation is counterbalanced by the activity of fusion-promoting factors. (A) COS-7 cells were cotransfected with 0.25  g
of a GDAP1 expression vector and 0.25  g of an empty vector (a–c), a vector coding for Drp1 (d–f), or dominant-negative Drp1(K38A) (g–i). 17 h after
transfection, cells were counterstained with MitoTracker Red. Fixed cells were probed with anti-GDAP1 and anti-myc antibodies. (B) In analogy to the
fission-blocking approach with Drp1(K38A), cotransfections of GDAP1 were performed with the fusion-inducing Mfn1 (a) or Mfn2 (c), or with the activity-
deficient mutants Mfn1(K88T) or Mfn2(K109A) (b, d). Representative confocal images (0.3- m sections) from three independent experiments are shown.
The results were quantified (A, j and B, e) to show the percentage of transfected cells that express both proteins and belong to different mitochondrial
classifications (n   500 cells per condition). Bars, 10  m. 
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timing and extent of mitochondrial fusion was observed in cell
hybrids of cells that were transfected with mtDsRed fused with
cells transfected with GDAP1 (Fig. 6, d–g). Thus, GDAP1 over-
expression does not interfere significantly with mitochondrial fu-
sion, and indicates that GDAP1 is a fission-inducing factor.
 
GDAP1 knock-down causes elongated 
mitochondria
 
To confirm that GDAP1 is regulating the mitochondrial mor-
phology, we performed RNA interference (RNAi) knock-down
experiments in N1E-115 neuroblastoma cells that endogenously
express GDAP1. We were able to reduce GDAP1 expression
levels by 60% (Fig. 7 A, a and b). This reduction could not
be determined reliably at the single-cell level by immunocy-
tochemistry. Thus, we counted at least 750 randomly chosen
cells per condition in blinded experiments. Transfections with
GDAP1-specific RNAi led to an increase of cells with a tubular
mitochondrial morphology compared with untransfected or con-
trol transfected cells (Fig.7 B); this further substantiated our
conclusion that GDAP1 promotes mitochondrial fission.
 
Disease-associated truncated GDAP1 
proteins fail to reach the mitochondria
 
We next asked whether mutations of GDAP1 found in patients
who have CMT have lost their mitochondrial targeting and/or the
ability to induce fission of mitochondria. To answer this question,
we generated a set of GDAP1 expression constructs, that repre-
sents three different stop mutations and five different point muta-
tions (Fig. 9) that were identified previously in patients who had
CMT (Baxter et al., 2002; Cuesta et al., 2002; Nelis et al., 2002;
Ammar et al., 2003; Azzedine et al., 2003; Boerkoel et al., 2003;
Senderek et al., 2003; Di Maria et al., 2004). Analysis in trans-
fected COS-7 cells revealed that the truncated proteins GDAP1
T288fs290X and GDAP1 S194X were not targeted efficiently to
mitochondria, but were localized diffusely throughout the cell
(Fig. 8 A, a–f). No mitochondrial fragmentation-inducing activity
was associated with these mutants (Fig. 8 A, b, e, h). The product
Figure 6. GDAP1 expression does not block mitochondrial fusion. HeLa
cells that were transfected transiently with mtDsRed were coplated with
HeLa cells, which were transfected transiently with mtGFP (a–c) or GDAP1
(d–f). Cells were fused with PEG and cultivated in the presence of cyclo-
heximide. 3–6 h after PEG fusion, the cell hybrids were analyzed for fusion
of the mitochondrial markers. Cell hybrids with no mitochondrial fusion
(a, d), with partial mitochondrial fusion (b, e), and with full mitochondrial
fusion (c, f) are depicted in single-plane confocal pictures. Cell hybrids
were counted from three independent experiments (n   120 hybrids per
time point). The percentage of hybrids with the different degrees of mito-
chondrial fusion at the time points indicated is shown (g). Bars, 10  m.
Figure 7. GDAP1 knock-down leads to elongation of mitochondria. Neu-
roblastoma N1E-115 cells were transfected with double-stranded small
interfering RNA against GDAP1, with the scrambled control, or were left
untransfected. (A, a) Equal amounts of cell lysates were separated and
immunoblotted against GDAP1 and  -actin as loading control. (b) The
relative expression levels of GDAP1 in correlation to the  -actin levels are
represented as the mean of three independent transfections. (B) The influ-
ence of GDAP1 knock-down on the mitochondrial architecture was quanti-
fied by counting in blinded experiments. At least 750 cells per condition
were counted from three independent experiments. Transfection with
GDAP1-specific small interfering RNA leads to a significant increase in
tubular mitochondria (probability   chi square   0.0001), whereas the
control transfection did not change the mitochondrial architecture (proba-
bility   chi square   0.5). 
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of the shortest construct, GDAP1(Q163X), was not detectable
with our antisera after transfection, although the epitope was
present in the sequence (see Fig. S1; Fig. 8 A, g). We favor the in-
terpretation that the GDAP1(Q163X) mutation generates a highly
unstable protein, which suggests that the corresponding disease
allele behaves like a null mutation.
 
The COOH-terminal transmembrane 
domain of GDAP1 contains the 
mitochondrial-targeting information
 
Computer analysis revealed that GDAP1 carries no canonical
mitochondrial targeting signal (unpublished data). Because the
GDAP1 truncation T288fsX290 apparently has lost the mito-
chondrial-targeting information, the deleted 68 COOH-terminal
amino acids are likely to harbor such signals. To assess this is-
sue in more detail, we generated fusion proteins in which por-
tions of GDAP1 were linked to the COOH terminus of EGFP.
A full-length EGFP-GDAP1 fusion protein, colocalized with
MitoTracker, demonstrated that the EGFP tagging allows effi-
cient mitochondrial targeting in transfected COS-7 cells (Fig. 8
B, a–c). As expected, the last 78 amino acids of GDAP1 (EGFP-
GDAP1
 
280–358
 
) were sufficient for mitochondrial localization
(Fig. 8 B, d–f), and confirmed that the signal is close to the
COOH terminus. Our further experimental strategy was based
Figure 8. The COOH terminus of GDAP1 bears the mitochondrial-targeting signal. (A) Transiently transfected COS-7 cells were counterstained with
MitoTracker Red before fixation; this was followed by GDAP1-antibody staining. The frame shift mutation GDAP1(T288fs290X) (a–c) and the stop muta-
tion GDAP1(S194X) (d–f) have lost mitochondrial targeting. The shortest truncation tested, GDAP1(Q163X), was not detectable (g–i). (B) EGFP was fused
to the NH2 terminus of the GDAP1 full-length protein (a–c), or the COOH-terminal parts of GDAP1 coding for the hydrophobic domains (HD) (d–f), for the
first hydrophobic domain (g–i) or the second hydrophobic domain only (j–l). EGFP alone is not appreciably found in mitochondria (m–o). All images rep-
resent single 0.3- m sections. All bars, 10  m. (C) Schematic representation of known mammalian tail-anchored proteins that regulate the mitochondrial
morphology. All proteins expose the NH2 terminus with the predicted catalytic domains (pink box, GTPase domain; red box, GST-N; blue box, GST-C)
toward the cytosol. Hydrophobic domains are in yellow. For GDAP1, the exact localization of the hydrophobic domain 1 and of the COOH terminus
remains unsolved (dashed box). IM, inner membrane; OM, outer membrane. 
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on the knowledge that mitochondrial proteins with a COOH-ter-
minal hydrophobic domain, surrounded by basic amino acids,
are targeted to the outer mitochondrial membrane (Kutay et
al., 1993). Mfn2 belongs to this class of proteins, called “tail-
anchored proteins.” For Mfn2, proper targeting requires the two
transmembrane domains surrounded by basic amino acids, and
coiled-coiled domains (Rojo et al., 2002). For GDAP1, the situ-
ation seems to be related, but different. An EGFP–fusion protein
with the first hydrophobic domain, including its flanking re-
gions (EGFP-GDAP1
 
280–316
 
), is not targeted to mitochondria
(Fig. 8 B, g–i). However, the second hydrophobic domain and
flanking regions are sufficient to direct an EGFP–fusion protein
(EGFP-GDAP1
 
308–358
 
) to mitochondria (Fig. 8 B, j–l). Notably,
cells with a particularly high expression of fusion protein exhib-
ited an additional perinuclear staining (Fig. 8 B, f and l), which
likely was an artifact of overexpression.
 
Disease-associated point mutations 
affect the ability of GDAP1 to induce 
fragmentation of mitochondria
 
Mutations leading to motor and sensory neuropathies are likely to
yield important information about particular GDAP1 domains that
are required for the proper function of the protein. Thus, we tested
various 
 
GDAP1
 
 point mutations (Fig. 9 A; M116H, R120Q,
R161H, R282C, R310Q), in addition to the truncation mutants that
were described above. Each of the selected point mutant forms
of GDAP1 protein was targeted to mitochondria in transfected
COS-7 cells (for examples, see Fig. 9 B). However, most interest-
ingly, the influence on the mitochondrial architecture differed among
the point mutants tested. Each mutant showed some impairment in
the ability to induce fragmentation compared with wild-type GDAP1
protein, as indicated by the variable reduction of the fraction of
cells with only fragmented mitochondria (Fig. 9 C, a). The mu-
tants R161H and R310Q were completely inactive with respect to
the promotion of mitochondrial fragmentation, and showed mor-
phologies that were comparable to those seen in control transfec-
tions. We conclude that GDAP1 mutations that are found in pa-
tients who have CMT are defective in the ability of GDAP1 to in-
duce mitochondrial fragmentation, albeit to different degrees.
 
Discussion
 
We have identified GDAP1 as a novel regulator of mito-
chondria. GDAP1 is a component of the outer mitochondrial
Figure 9. Disease-related GDAP1 point
mutations are impaired in fission activity.
(A) Schematic representation of the GDAP1
protein with known CMT-associated point mu-
tations indicated. Mutations examined are in
bold. (B) Transfected COS-7 cells were coun-
terstained with MitoTracker Red before fixation
and were stained with GDAP1 antibodies. All
tested point mutations colocalized with mito-
chondria. Representative confocal pictures of
GDAP1(R120Q) (a–d) and GDAP1(R310Q)
(e–h) are shown. Bars in c, g, 10  m; bars in
d, h, 2  m. (C, a) The influence on the mito-
chondrial architecture was quantified for all
point mutations. We counted at least 500 cells
per point mutation that expressed GDAP1 or
one of the point mutations tested. The cells
were grouped into five mitochondrial classifi-
cations. All changes are highly significant
(probability   chi square   0.001, compar-
ing all conditions versus GDAP1 [wild-type]
transfected cells in a contingency analysis).
The expression levels of the tested GDAP1
point mutations were comparable to the
GDAP1 wild-type protein in transfected COS-7
cells (quantified as ratio of the anti-GDAP1/
anti- -actin signals in cell lysates of sister
plates [b]).JCB • VOLUME 170 • NUMBER 7 • 2005 1076
membrane and, in concert with other proteins, influences the
balance between fused and fragmented mitochondria. The mi-
tochondrial localization of GDAP1 is required for this activity;
the necessary information for proper organelle targeting is con-
tained within the COOH-terminal part of the polypeptide.
Analysis of GDAP1 mutations associated with hereditary mo-
tor and sensory neuropathies revealed that both features of
GDAP1—proper localization and the modulating activity on
mitochondria—are likely to be crucial for the functional integ-
rity of myelinated peripheral nerves.
It is well-established that the nervous system is espe-
cially sensitive to mitochondrial dysfunction (Bouillot et al.,
2002; Bossy-Wetzel et al., 2003; Finsterer, 2004). Further-
more, a critical role for mitochondria is discussed in the con-
text of diseases and syndromes with liability to neuropathies,
including diabetes (Vincent et al., 2004) or degeneration re-
lated to ageing (Bossy-Wetzel et al., 2003). We have found
that GDAP1, the product of the disease-causing gene in par-
ticular forms of the neurodegenerative disorder CMT, is a key
regulator of mitochondrial fragmentation. The observed frag-
mentation effect most likely is linked closely to mitochondrial
fission. This important specific aspect of the biology of mito-
chondria has been appreciated fully only recently (Mozdy and
Shaw, 2003; Chen and Chan, 2004; Rube and van der Bliek,
2004). In relation to diseases, two proteins that are involved in
mitochondrial fusion are involved in neuropathies (Bossy-
Wetzel et al., 2003). Mutations in the dynamin-related GTP-
ase, OPA-1, lead to optic atrophy (Delettre et al., 2000); mu-
tations in MFN2 were linked recently to CMT2A (Zuchner et
al., 2004). We describe that GDAP1 also takes part in the reg-
ulation of mitochondrial dynamics by promoting mitochon-
drial fission. The fission effect is not secondary as a result of
the induction of apoptosis or the reduction of the   m.
GDAP1-induced mitochondrial fragmentation was counter-
acted by the fusion inducing factors, Mfn1 and Mfn2 and the
dominant negative fission-blocking Drp1(K38A). PEG-medi-
ated cell fusions further demonstrated that GDAP1 expression
does not interfere with mitochondrial fusion. These findings
suggest that common elements in the disease mechanisms of
CMT are caused by mutations in GDAP1 and MFN2, although
GDAP1 and Mfn2 have opposite effects on the mitochondrial
morphology. The relation between GDAP1 and Mfn2 is in-
triguing if the two phenotypes of the associated diseases are
compared. Mfn2 has been described exclusively in the context
of axonal neuropathies in CMT2A, which indicates a neuronal
basis of the disease mechanism. GDAP1 has been associated
with axonal, demyelinating, and mixed phenotypes in CMT.
Thus, a neuronal disease origin also might be favored in CMT
caused by mutations in GDAP1 if an altered mitochondrial
regulation by mutations in GDAP1 and MFN2 is put forward
as the hypothetic basis of both genetically distinct disorders.
However, we found that GDAP1 is expressed by myelinating
Schwann cells as well as motor and sensory neurons; it is pos-
sible that the disease primarily affects Schwann cells, neu-
rons, or both. Cell-type specific elimination of GDAP1 indi-
vidually from neurons or Schwann cells will be required to
resolve this issue.
Truncations and point mutations in GDAP1 are associ-
ated with CMT. Our results indicate that the COOH-terminal
truncations that were tested have lost mitochondrial localiza-
tion, whereas the examined GDAP1 proteins carrying missense
mutations remained correctly targeted to mitochondria. These
data are consistent with a recent report on the subcellular local-
ization and effects of some GDAP1 mutations (Pedrola et al.,
2005). We further demonstrate that GDAP1 proteins carrying
disease-related mutations have lost the ability to induce mito-
chondrial fragmentation to various degrees. However, we have
been unable to correlate the activity differences to disease on-
set, severity, and/or pathology. The variability of the pheno-
types seems to be too high, even between relatives with the
identical mutation (Azzedine et al., 2003).
The mitochondrial network is dynamic, and shifting the
balance of fusion and fission is a major regulatory mechanism.
Although the functional consequences of these events are un-
derstood poorly, it is obvious that complex and divergent stim-
uli influence the mitochondrial appearance (Goglia et al., 1999;
Bach et al., 2003; Bossy-Wetzel et al., 2003; Honda and Hi-
rose, 2003). The finding that mutations in genes affect this pro-
cess in hereditary motor and sensory neuropathies suggests that
myelinated peripheral nerves are particularly dependent on the
proper function and control of this system. Whether this vul-
nerability is the consequence of a deregulation of the mito-
chondrial architecture or an impaired mitochondrial transport
(Shy, 2004) remains to be determined.
Recently, evidence for mitochondrial fusion intermedi-
ates and an Mfn complex mediating mitochondrial tethering
was provided (Koshiba et al., 2004; Meeusen et al., 2004).
How the potential GST protein GDAP1, might, on a molecular
level, be involved in the regulation of the mitochondrial archi-
tecture remains elusive. On a highly speculative note, the mito-
chondrial morphology is dependent on glutathione (GSH). De-
pletion of GSH leads to mitochondrial fusion, and results in a
tubular mitochondrial network (Soltys and Gupta, 1994), al-
though this effect may not be based solely on the GSH concen-
tration (Bowes and Gupta, 2005). It remains unknown whether
these are genuine hints that GDAP1 is a mitochondrial fission-
inducing factor that is dependent on GSH.
In summary, we introduce GDAP1 as a key regulator of
mitochondrial dynamics. If this activity is lost, the integrity of
peripheral nerves is disturbed and leads to myelin and axonal
defects. We anticipate that further elucidation of the cellular
and molecular mechanisms that underlie the pathology of
GDAP1-based CMT will help to uncover the function of
GDAP1 and mitochondrial dynamics in peripheral nerves.
Conversely, further examination of the molecular function of
GDAP1 in the biology of mitochondria will contribute signifi-
cantly to our basic understanding of CMT.
Materials and methods
RNA and protein isolation from mouse tissue
Tissues of C57BL/6 mice were isolated at postnatal day 68, flash frozen
in liquid nitrogen, and stored at  80 C. Total RNA and protein was ex-
tracted with Trizol reagent using a Polytron PT homogenizer, according to
the manufacturer’s instructions (Invitrogen). RNA was quantified by pho-GDAP1 IS A NOVEL MITOCHONDRIAL REGULATOR • NIEMANN ET AL. 1077
tometry, and protein concentrations were determined using the Dc-Protein
Assay (Bio-Rad Laboratories).
Constructs
GDAP1 cDNA was amplified by RT-PCR from adult mouse brain using the
following primers: 5 -CGGATCCATGGCTCGGAGGCAGGAC-3 , 5 -
CGTCGACTAGAAATAATTTGGTCTGG-3 . GDAP1-like-1 cDNA was
cloned using 5 -CGGATCCATGGCGACCCCCAAC-3  and 5 -CCCAGC-
CAGCTCTAGATGT-3 . Point mutations and truncations were generated
by PCR with appropriate primer pairs. All cDNAs were cloned into the
pGEM-T vector and verified by sequencing. The cDNAs were subcloned
into pcDNA3.1 (Invitrogen) or EGFP-C1 (CLONTECH Laboratories, Inc.).
Alternatively, the coding region for EGFP was replaced by the HA epitope
(HA-C1 vector, provided by A. Hirschy, Swiss Federal Institute of Technol-
ogy, Zürich, Switzerland). EGFP-hTOM7 and EGFP-hFis1 expression con-
structs were provided M. Ryan (La Trobe University, Melbourne, Austra-
lia). Mfn1-10xMyc, Mfn1(K88T)-10xMyc, Mfn2-16xMyc, Mfn2(K109A)-
16xMyc, Drp1-6xMyc, and Drp(K38A)6xMyc were provided by D. Chan
(California Institute of Technology, Pasadena, California). MtDsRed2 and
mtGFP were from CLONTECH Laboratories, Inc.
Cell culture
Rat Schwann cells were prepared essentially as described by Brockes et
al. (1979). Cells were grown in Schwann cell medium (DME; Invitrogen),
containing 10% FCS, 4  g/ml glial growth factor (crude pituitary extract
(Sigma-Aldrich), and 4  M forskolin (Sigma-Aldrich). For growth arrest,
cells were incubated for 3 d in low serum medium (DME/F12 medium
(Invitrogen), 0.5% FCS, 4  M forskolin, 100  g/ml human apo-transfer-
rin, 60 ng/ml progesterone, 16  g/ml putrescine, 10  g/ml insulin, 400
ng/ml L-thyroxin, 160 ng/ml selenium, 0.02 ng/ml triiodothyronine, and
300  g/ml BSA (Fluka). Supplements were from Sigma-Aldrich, unless
stated otherwise. COS-7 cells, HeLa cells, and N1E-115 cells were main-
tained in DME containing 10% FCS, 100 units/ml penicillin, and 100
 g/ml streptomycin (Invitrogen). COS-7 and HeLa cells were transfected
using Fugene 6, according to the recommendations of the manufacturer
(Roche). RNAi transfections on N1E-115 cells were done with 1.7  g/ml
lipofectamine 2000 (Invitrogen) and 55 nM Stealth RNAi (Invitrogen;
GDAP1-specific: GGCCA CUCAG AUCAU UGAUU AUCUU; control:
GGCAC UCCUA GGUUA AUUAU ACCUU). The cells were fixed or har-
vested 48 h after the start of transfection.
Cell fractionation
The differential centrifugation protocol to enrich for mitochondria was
adopted from Graham (2004). Proteinase digestion was performed as de-
scribed elsewhere (Olichon et al., 2002). Proteinase K (50  g/ml) was
added to the cell fractionation buffer with increasing concentrations of dig-
itonin, or SDS. After 30 min on ice, the digest was stopped with 0.2 mM
PMSF. To test for membrane integration of GDAP1, the first mitochondrial
pellet from the differential centrifugation procedure was split and resus-
pended with a vortex mixer for 30 s at full speed in four different buffers:
the homogenization buffer with 0.25 M sucrose (control), the control
buffer plus 1 M sodium chloride (1 M NaCl), the control buffer plus 0.1%
Triton X-100, or in 0.1 M sodium carbonate pH 11.0 (carbonate). The sam-
ples were centrifuged again for 20 min at 8000 g, 4 C. Equal volumes of
the supernatants and pellets were analyzed by Western blot (Olichon et
al., 2002; Stojanovski et al., 2004).
Cell fusions
For cell fusion, HeLa cells were transfected transiently with mtDsRed, mt-
GFP, or GDAP1. 8 h after the start of transfection, the cells were coplated
on coverslips and cultivated overnight. The next morning, cycloheximide
was added to the medium (1 mM). After 30 min, the cells were fused on a
drop of prewarmed 50% w/v PEG 6000 (Sigma-Aldrich) in PBS/glucose
(1 g/l) for 2 min. The cells were washed intensively with PBS/glucose and
were kept in cultivation medium plus cycloheximide.
Antibodies
Polyclonal rabbit anti-GDAP1 antisera were generated by Pineda. Two dif-
ferent peptides were used as antigen (peptide 1: MARRQDEARAGVPL;
peptide 2: FLDERTPRLMPDEGS). The antisera were used in a 1:7,500 dilu-
tion for Western blotting and 1:1,000 for immunofluorescence. Unless in-
dicated otherwise, the sera against peptide 1 (serum 1) and peptide 2
(serum 2) were used and gave identical results. For immunohistochemistry
of paraffin sections, we used serum 1, which was purified with the Mon-
tage antibody purification Kit (Millipore). The monoclonal mouse antibod-
ies against   actin (clone AC-74), neurofilament 160 (clone NN18), and
S-100  -subunit (clone SH-B1) were from Sigma-Aldrich. Monoclonal anti-
cytochrome  c antibody (clone 7H8.2C12 and clone 6H2.B4) and the
polyclonal rabbit anti-caspase3 antibody were obtained from BD Bio-
sciences. The monoclonal rat anti-HA (clone 3F10) was purchased from
Roche. The polyclonal rabbit anti-PDI antisera were provided by Dr. A.
Helenius (Swiss Federal Institute of Technology, Zürich, Switzerland).
Immunohistochemistry
Cells were fixed with 2.5% PFA/PBS for 30 min at room temperature.
Tissue was fixed overnight with 3.7% formalin, dehydrated, and embed-
ded in paraffin in a Tissue Processor TP1010 (Leica). 6- m sections were
prepared using a Rotary Microtome HM 330 (Microm). For immunohis-
tochemistry, fixed cells and rehydrated sections were incubated with
0.1% Triton X-100/PBS for 10 min. After washing with PBS, the speci-
mens were incubated with 10% goat serum in PBS for 1 h at room tem-
perature, followed by incubation with primary antibodies in 10% goat
serum/PBS for 90 min at room temperature or overnight at 4 C. After
washing, samples were exposed to appropriate secondary antibodies.
Cy3- and Cy5-conjugated antibodies were from the Jackson Laboratory,
secondary antibodies with Alexa-dyes from Molecular Probes. Samples
were incubated with DAPI (Roche) and mounted in Immu-Mount (Ther-
moShandon). Specimens were analyzed with a Zeiss Axiophot micro-
scope (Carl Zeiss Microimaging, Inc.). Alternatively, we used confocal
microscopy on an inverted microscope DM IRB/E equipped with a true
confocal scanner TCS SP1, a PL APO 63 /1.32 oil immersion objective
(Leica) as well as argon, helium–neon lasers. Image processing was
done on a Silicon Graphics workstation using Imaris (Bitplane AG). For
labeling of mitochondria, we used MitoTracker Red (Molecular Probes)
following the manufacturer’s recommendations. MitoTracker Red CM-
H2XRos was added to the medium in a final concentration of 0.5  M for
30 min. After this pulse, the cells were cultivated in growth medium with-
out dye for 10 min before fixation. To determine the relative uptake of
MitoTrackerH2XRos into transfected cells, we analyzed single-plane con-
focal images. Using ImageJ, we measured the relative fluorescence (RF)
intensity of MitoTrackerH2XRos and the area. We determined the RF/
area in transfected cells and in untransfected cells on the same picture.
For each picture, the RF/area of transfected cells was divided by the RF/
area of untransfected cells. The average and the standard deviation of
several pictures (n   6) were determined using two-tailed unpaired t test.
Western blotting
After SDS-PAGE, proteins were transferred onto polyvinylidene difluoride
membrane (Millipore). Blots were blocked with 10% nonfat dry milk pow-
der in TBS. The primary antibodies were diluted according to the manufac-
turer’s recommendation or as described above. Blots were washed with
0.05% Tween 20/TBS. Secondary antibodies were from Santa Cruz Bio-
technology, Inc., DakoCytomation, and Southern Biotechnology Associ-
ates, Inc. Immunoreactive bands were visualized by Western Lightning
(PerkinElmer) or CDP-Star (Roche).
Online supplemental material
Fig. S1 shows validation of GDAP1-specific antisera. Fig. S2 shows that
endogenous GDAP1 is found in mitochondria of Schwann cells and PNS
neurons.
We gratefully acknowledge the gift of reagents by Drs. A. Hirschy, M. Weg-
ner (University of Erlangen-Nürnberg, Erlangen, Germany), M. Ryan, D.
Chan, and A. Helenius and thank Dr. S. Atanasoski for support with the West-
ern blot analysis.
This work was supported by the Swiss National Science Foundation
and the National Center of Competence in Research “Neural Plasticity and
Repair” to U.S. and FIRB-RBAU01KJE4_002 to A. Schenone.
Submitted: 18 July 2005
Accepted: 22 August 2005
References
Ammar, N., E. Nelis, L. Merlini, N. Barisic, R. Amouri, C. Ceuterick, J.J. Mar-
tin, V. Timmerman, F. Hentati, and P. De Jonghe. 2003. Identification of
novel GDAP1 mutations causing autosomal recessive Charcot-Marie-
Tooth disease. Neuromuscul. Disord. 13:720–728.
Azzedine, H., M. Ruberg, D. Ente, C. Gilardeau, S. Perie, B. Wechsler, A.
Brice, E. LeGuern, and O. Dubourg. 2003. Variability of disease pro-
gression in a family with autosomal recessive CMT associated with a
S194X and new R310Q mutation in the GDAP1 gene. Neuromuscul.
Disord. 13:341–346.JCB • VOLUME 170 • NUMBER 7 • 2005 1078
Bach, D., S. Pich, F.X. Soriano, N. Vega, B. Baumgartner, J. Oriola, J.R.
Daugaard, J. Lloberas, M. Camps, J.R. Zierath, et al. 2003. Mitofusin-2
determines mitochondrial network architecture and mitochondrial me-
tabolism. A novel regulatory mechanism altered in obesity. J. Biol.
Chem. 278:17190–17197.
Baxter, R.V., K. Ben Othmane, J.M. Rochelle, J.E. Stajich, C. Hulette, S. Dew-
Knight, F. Hentati, M. Ben Hamida, S. Bel, J.E. Stenger, et al. 2002.
Ganglioside-induced differentiation-associated protein-1 is mutant in
Charcot-Marie-Tooth disease type 4A/8q21. Nat. Genet. 30:21–22.
Berger, P., E.E. Sirkowski, S.S. Scherer, and U. Suter. 2004. Expression analy-
sis of the N-Myc downstream-regulated gene 1 indicates that myelinat-
ing Schwann cells are the primary disease target in hereditary motor and
sensory neuropathy-Lom. Neurobiol. Dis. 17:290–299.
Berger, P., P. Young, and U. Suter. 2002. Molecular cell biology of Charcot-
Marie-Tooth disease. Neurogenetics. 4:1–15.
Boerkoel, C.F., H. Takashima, M. Nakagawa, S. Izumo, D. Armstrong, I. But-
ler, P. Mancias, S.C. Papasozomenos, L.Z. Stern, and J.R. Lupski. 2003.
CMT4A: identification of a Hispanic GDAP1 founder mutation. Ann.
Neurol. 53:400–405.
Bossy-Wetzel, E., M.J. Barsoum, A. Godzik, R. Schwarzenbacher, and S.A.
Lipton. 2003. Mitochondrial fission in apoptosis, neurodegeneration and
aging. Curr. Opin. Cell Biol. 15:706–716.
Bouillot, S., M.L. Martin-Negrier, A. Vital, X. Ferrer, A. Lagueny, D. Vincent,
M. Coquet, J.M. Orgogozo, B. Bloch, and C. Vita. 2002. Peripheral neu-
ropathy associated with mitochondrial disorders: 8 cases and review of
the literature. J. Peripher. Nerv. Syst. 7:213–220.
Bowes, T.J., and R.S. Gupta. 2005. Induction of mitochondrial fusion by cys-
teine-alkylators ethacrynic acid and N-ethylmaleimide. J. Cell Physiol.
202:796–804.
Brockes, J.P., K.L. Fields, and M.C. Raff. 1979. Studies on cultured rat
Schwann cells. I. Establishment of purified populations from cultures of
peripheral nerve. Brain Res. 165:105–118.
Chen, F., and M.T. Cushion. 1994. Use of fluorescent probes to investigate the
metabolic state of Pneumocystis carinii mitochondria. J. Eukaryot. Mi-
crobiol. 41:79S.
Chen, H., and D.C. Chan. 2004. Mitochondrial dynamics in mammals. Curr.
Top. Dev. Biol. 59:119–144.
Chen, H., S.A. Detmer, A.J. Ewald, E.E. Griffin, S.E. Fraser, and D.C. Chan. 2003.
Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and
are essential for embryonic development. J. Cell Biol. 160:189–200.
Cossarizza, A., M. Baccarani-Contri, G. Kalashnikova, and C. Franceschi.
1993. A new method for the cytofluorimetric analysis of mitochondrial
membrane potential using the J-aggregate forming lipophilic cation
5,5 ,6,6 -tetrachloro-1,1 ,3,3 -tetraethylbenzimidazolcarbocyanine io-
dide (JC-1). Biochem. Biophys. Res. Commun. 197:40–45.
Cuesta, A., L. Pedrola, T. Sevilla, J. Garcia-Planells, M.J. Chumillas, F. May-
ordomo, E. LeGuern, I. Marin, J.J. Vilchez, and F. Palau. 2002. The
gene encoding ganglioside-induced differentiation-associated protein 1
is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat. Genet.
30:22–25.
Delettre, C., G. Lenaers, J.M. Griffoin, N. Gigarel, C. Lorenzo, P. Belenguer, L.
Pelloquin, J. Grosgeorge, C. Turc-Carel, E. Perret, et al. 2000. Nuclear
gene OPA1, encoding a mitochondrial dynamin-related protein, is mu-
tated in dominant optic atrophy. Nat. Genet. 26:207–210.
Di Maria, E., R. Gulli, P. Balestra, D. Cassandrini, S. Pigullo, L. Doria-Lamba,
M. Bado, A. Schenone, F. Ajmar, P. Mandich, and E. Bellone. 2004. A
novel mutation of GDAP1 associated with Charcot-Marie-Tooth disease
in three Italian families: evidence for a founder effect. J. Neurol. Neuro-
surg. Psychiatry. 75:1495–1498.
Finsterer, J. 2004. Mitochondriopathies. Eur. J. Neurol. 11:163–186.
Goglia, F., M. Moreno, and A. Lanni. 1999. Action of thyroid hormones at the
cellular level: the mitochondrial target. FEBS Lett. 452:115–120.
Graham, J.M. 2004. Isolation of mitochondria from tissues and cells by differ-
ential centrifugation. In Current Protocols in Cell Biology. J.S. Bonifa-
cino, J.B. Harford, J. Lippincott-Schwartz, and K.M. Yamada, editors.
Wiley InterScience, New York. 3.3.2.
Honda, S., and S. Hirose. 2003. Stage-specific enhanced expression of mito-
chondrial fusion and fission factors during spermatogenesis in rat testis.
Biochem. Biophys. Res. Commun. 311:424–432.
James, D.I., P.A. Parone, Y. Mattenberger, and J.C. Martinou. 2003. hFis1, a
novel component of the mammalian mitochondrial fission machinery. J.
Biol. Chem. 278:36373–36379.
Koshiba, T., S.A. Detmer, J.T. Kaiser, H. Chen, J.M. McCaffery, and D.C.
Chan. 2004. Structural basis of mitochondrial tethering by mitofusin
complexes. Science. 305:858–862.
Kutay, U., E. Hartmann, and T.A. Rapoport. 1993. A class of membrane pro-
teins with a C-terminal anchor. Trends Cell Biol. 3:72–75.
Lee, Y.J., S.Y. Jeong, M. Karbowski, C.L. Smith, and R.J. Youle. 2004. Roles
of the mammalian mitochondrial fission and fusion mediators Fis1,
Drp1, and Opa1 in apoptosis. Mol. Biol. Cell. 15:5001–5011.
Legros, F., A. Lombes, P. Frachon, and M. Rojo. 2002. Mitochondrial fusion in
human cells is efficient, requires the inner membrane potential, and is
mediated by mitofusins. Mol. Biol. Cell. 13:4343–4354.
Liu, H., T. Nakagawa, T. Kanematsu, T. Uchida, and S. Tsuji. 1999. Isolation of
10 differentially expressed cDNAs in differentiated Neuro2a cells induced
through controlled expression of the GD3 synthase gene. J. Neurochem.
72:1781–1790.
Marco, A., A. Cuesta, L. Pedrola, F. Palau, and I. Marin. 2004. Evolutionary
and structural analyses of GDAP1, involved in Charcot-Marie-Tooth dis-
ease, characterize a novel class of glutathione transferase-related genes.
Mol. Biol. Evol. 21:176–187.
Mattenberger, Y., D.I. James, and J.C. Martinou. 2003. Fusion of mitochondria in
mammalian cells is dependent on the mitochondrial inner membrane po-
tential and independent of microtubules or actin. FEBS Lett. 538:53–59.
Meeusen, S., J.M. McCaffery, and J. Nunnari. 2004. Mitochondrial fusion inter-
mediates revealed in vitro. Science. 305:1747–1752.
Mozdy, A.D., and J.M. Shaw. 2003. A fuzzy mitochondrial fusion apparatus
comes into focus. Nat. Rev. Mol. Cell Biol. 4:468–478.
Nelis, E., S. Erdem, P.Y. Van Den Bergh, M.C. Belpaire-Dethiou, C. Ceuterick,
V. Van Gerwen, A. Cuesta, L. Pedrola, F. Palau, A.A. Gabreels-Festen,
et al. 2002. Mutations in GDAP1: autosomal recessive CMT with de-
myelination and axonopathy. Neurology. 59:1865–1872.
Olichon, A., L.J. Emorine, E. Descoins, L. Pelloquin, L. Brichese, N. Gas, E.
Guillou, C. Delettre, A. Valette, C.P. Hamel, et al. 2002. The human dy-
namin-related protein OPA1 is anchored to the mitochondrial inner
membrane facing the inter-membrane space. FEBS Lett. 523:171–176.
Pedrola, L., A. Espert, X. Wu, R. Claramunt, M.E. Shy, and F. Palau. 2005.
GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is
expressed in neurons and is associated with mitochondria. Hum. Mol.
Genet. 14:1087–1094.
Rojo, M., F. Legros, D. Chateau, and A. Lombes. 2002. Membrane topology
and mitochondrial targeting of mitofusins, ubiquitous mammalian ho-
mologs of the transmembrane GTPase Fzo. J. Cell Sci. 115:1663–1674.
Rube, D.A., and A.M. van der Bliek. 2004. Mitochondrial morphology is dy-
namic and varied. Mol. Cell. Biochem. 256-257:331–339.
Santel, A., S. Frank, B. Gaume, M. Herrler, R.J. Youle, and M.T. Fuller. 2003.
Mitofusin-1 protein is a generally expressed mediator of mitochondrial
fusion in mammalian cells. J. Cell Sci. 116:2763–2774.
Santel, A., and M.T. Fuller. 2001. Control of mitochondrial morphology by a
human mitofusin. J. Cell Sci. 114:867–874.
Senderek, J., C. Bergmann, V.T. Ramaekers, E. Nelis, G. Bernert, A. Ma-
kowski, S. Zuchner, P. De Jonghe, S. Rudnik-Schoneborn, K. Zerres,
and J.M. Schroder. 2003. Mutations in the ganglioside-induced differen-
tiation-associated protein-1 (GDAP1) gene in intermediate type autoso-
mal recessive Charcot-Marie-Tooth neuropathy. Brain. 126:642–649.
Shy, M.E. 2004. Charcot-Marie-Tooth disease: an update. Curr. Opin. Neurol.
17:579–585.
Smirnova, E., D.L. Shurland, S.N. Ryazantsev, and A.M. van der Bliek. 1998. A
human dynamin-related protein controls the distribution of mitochondria.
J. Cell Biol. 143:351–358.
Sogo, L.F., and M.P. Yaffe. 1994. Regulation of mitochondrial morphology and
inheritance by Mdm10p, a protein of the mitochondrial outer membrane.
J. Cell Biol. 126:1361–1373.
Soltys, B.J., and R.S. Gupta. 1994. Changes in mitochondrial shape and distri-
bution induced by ethacrynic acid and the transient formation of a mito-
chondrial reticulum. J. Cell. Physiol. 159:281–294.
Stojanovski, D., O.S. Koutsopoulos, K. Okamoto, and M.T. Ryan. 2004. Levels
of human Fis1 at the mitochondrial outer membrane regulate mitochon-
drial morphology. J. Cell Sci. 117:1201–1210.
Suter, U., and S.S. Scherer. 2003. Disease mechanisms in inherited neuropathies.
Nat. Rev. Neurosci. 4:714–726.
Vincent, A.M., J.W. Russell, P. Low, and E.L. Feldman. 2004. Oxidative stress
in the pathogenesis of diabetic neuropathy. Endocr. Rev. 25:612–628.
Yoon, Y. 2004. Sharpening the scissors: mitochondrial fission with aid. Cell
Biochem. Biophys. 41:193–206.
Zuchner, S., I.V. Mersiyanova, M. Muglia, N. Bissar-Tadmouri, J. Rochelle,
E.L. Dadali, M. Zappia, E. Nelis, A. Patitucci, J. Senderek, et al. 2004.
Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-
Marie-Tooth neuropathy type 2A. Nat. Genet. 36:449–451.